Translational medicine: new hope or artful design of big pharma?
Abstract
This review is devoted to translational medicine as novel integrative approach for novel treatment development. Basic aspects and mechanisms of implementation of translational medicine armamentarium in certain biomedical researches are addressed.
References
1. FitzGerald G. Anticipating change in drug development: the emerging era of translational medicine and therapeutics // Nat Rev Drug Discov. 2005 Oct;4(10):815-8.
2. http://government.ru/docs/16428/.
3. http://www.fda.gov/drugs/drugsafety/ucm264059.htm.
4. http://www.forbes.com/sites/matthewherper/2013/06/06/what-the-fdas-avandia-decision-means-for-the-future/.
5. http://www.oecd.org/sti/biotech/35641467.pdf.
6. https://clinicaltrials.gov/ct2/show/NCT01643590?term=STOP-HF&rank=2.
7. https://en.wikipedia.org/wiki/ApoA-1_Milano.
8. Mankoff S., Brander C., Ferrone S., Marincola F. Lost in Translation: Obstacles to Translational Medicine. // Journal of Translational Medicine 2004, 2:14.
9. Namsolleck P., Recarti C., Foulquier S. AT2 Receptor and Tissue Injury: Therapeutic Implications. // Curr Hypertens Rep. 2014; 16(2): 416.
10. Schwartz G., Olsson A., Abt M. et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. // N Engl J Med 2012; 367:2089-2099.
11. Seals D. Translational physiology: from molecules to public health. // J Physiol 591.14 (2013) pp 3457—3469.
12. Strauss M. Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. Unraveling the ARB-MI Paradox. // Circulation. 2006; 114: 838-854.
13. Tall A., Yvan-Charvet L., Wang N. The Failure of Torcetrapib. Was it the Molecule or the Mechanism? // Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27: 257-260.
Review
For citations:
Ashikhmin Y.I. Translational medicine: new hope or artful design of big pharma? Pharmacogenetics and Pharmacogenomics. 2015;(1):40-44. (In Russ.)
Views:
1842
JATS XML
Email this article 
Post a Comment 